A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

NCT07069270 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER_GOV

Sponsor class

Conditions

Vunakizumab
Adebrelimab
Small Cell Lung Cancer

Interventions

DRUG: Vunakizumab (IL-17A inhibitor)
DRUG: Adebrelimab
DRUG: Chemotherapy

Sponsor

Fujian Cancer Hospital